Wu et al. reported on Acute Kidney Injury Associated With Remdesivir via a Comprehensive Pharmacovigilance Analysis of COVID-19 Reports; why did CDC, FDA, Fauci, Walensky, NIH, Francis Collins ignore?
by Paul Alexander
Acute kidney injury (AKI) events occurred in cases of male patients & those above the age of 65 years; detected a significant association between remdesivir & AKI: ROR = 2.81, 95% CI (2.48, 3.18).
‘More AKI events occurred in cases of male patients and those above the age of 65 years. We detected a significant association between remdesivir and AKI: ROR = 2.81, 95% CI (2.48, 3.18). The association was stronger after the propensity score matching ROR = 3.85, 95% CI (3.11, 4.78). The mean time to AKI event onset was 4.91 ± 7.25 days in COVID-19 cases with remdesivir therapy. The fatality proportion was 36.45% in AKI cases with remdesivir treatment. This pharmacovigilance study identified a significant association between AKI events and remdesivir treatment in COVID-19 patients by mining FAERS real-world big data. Although causality was not confirmed, the association between remdesivir and AKI should not be ignored, especially in the older, male COVID-19 inpatients.’